We seem to be rapidly approaching an inflection point, brought on by the compounding distributors such as Hims, that will need to be resolved: there are probably more people on the compounded version of this drug than most suspect and that number is growing by the tens of thousands every day. Meanwhile, Norvo Nordisk is trying to shut down this channel of distribution. That would be a bad idea and I think the FDA must be aware of that. This conflict between NN and the compounders needs to be resolved.
Personally I think the promise of this drug makes it a moral issue and have little sympathy for NNs position here: they will need to capitulate on their control over it and accept some kind of suboptimal pricing agreement. The potential positive outcomes of this drug supersedes their sole claim to it IMO.